MAP2K3 and non-small cell lung carcinoma: Indeed, by analyzing a panel of seven NSCLC derived lines (H23, Hop62, H157, H226, H460, H661, and H1299), they demonstrated that lines with high MKK3 protein levels are less responsive to cisplatin through a constitutive hyperactivation of the p38MAPK pathway, which in turn inhibits the MKK6 mRNA levels, suggesting in tumor cell-context, the existence of a regulatory mechanism only described in nontransformed MEF cells [34].